@article{633a4308a8a84a77b916d06d43449ac5,
title = "Differential Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Profiles After Allergic Reactions to Messenger RNA Coronavirus Disease 2019 Vaccine",
abstract = "Allergic symptoms after messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines occur in up to 2% of recipients. Compared to nonallergic controls (n = 18), individuals with immediate allergic reactions to mRNA COVID-19 vaccines (n = 8) mounted lower immunoglobulin G1 (IgG1) to multiple antigenic targets in severe acute respiratory syndrome coronavirus 2 spike following vaccination, with significantly lower IgG1 to full-length spike (P =. 04). Individuals with immediate allergic reactions to mRNA COVID-19 vaccines bound Fcγreceptors similarly to nonallergic controls. Although there was a trend toward an overall reduction in opsonophagocytic function in individuals with immediate allergic reactions compared to nonallergic controls, allergic patients produced functional antibodies exhibiting a high ratio of opsonophagocytic function to IgG1 titer.",
keywords = "COVID-19, Moderna, Pfizer, SARS-CoV-2, anaphylaxis, humoral immunity, hypersensitivity, messenger RNA, systems serology, vaccination",
author = "Maron, {Jenny S.} and Michelle Conroy and Vivek Naranbai and Upeka Samarakoon and Tina Motazedi and Farmer, {Jocelyn R.} and Esther Freeman and Aleena Banerji and Bartsch, {Yannic C.} and Gregory, {David J.} and Poznansky, {Mark C.} and Galit Alter and Blumenthal, {Kimberly G.}",
note = "Funding Information: Potential conflicts of interest. M. C. has received consulting fees from Exicure and Homology Medicines. V. N. received support from a Medscape Young Investigators Lung Cancer award. J. R. F. holds investigator-initiated grants from Bristol-Myers Squibb and Pfizer and is on the advisory board for Bristol-Myers Squibb and CSL Behring. E. F. is co-author for UpToDate on COVID-19 dermatology; has received financial support from the International League of Dermatologic Societies; and is a member of the American Academy of Dermatology COVID-19 Task Force. A. B. receives royalties from UpToDate. D. J. G. reports that he is a current employee and stockholder of ReNAgade Therapeutics Inc; this relationship did not exist until after this work was submitted for publication. G. A. is founder and/or employee of SeromYx Systems, Inc and Leyden Labs and is on the scientific advisory board for Sanofi. K. G. B. has received personal fees from Weekley, Schulte, Valdes, Murman, Tonelli; Vasios, Kelly, and Strollo, P.A.; and Piedmont Liability Trust. K. G. B. has also received grants from the National Institutes of Health (UM1AI109565) and royalties from UpToDate. All other authors report no potential conflicts of interest. Funding Information: This work was supported by the Massachusetts General Hospital's Transformational Scholar Award and COVID Junior Investigator Support Initiative and by the National Institutes of Health (grant number T32 AI007245). Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.",
year = "2022",
month = oct,
day = "1",
doi = "10.1093/infdis/jiac107",
language = "English (US)",
volume = "226",
pages = "1231--1236",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "7",
}